dr. sznol on patient selection for combination therapy in mrcc
Published 5 years ago • 93 plays • Length 1:25Download video MP4
Download video MP3
Similar videos
-
1:02
dr. sznol on immunotherapy in patients with rcc
-
1:29
dr. sznol on unanswered questions with immunotherapy in rcc
-
2:18
dr. joseph on selecting frontline therapy in mrcc
-
1:17
dr. sznol on immunotherapy combinations for the treatment of melanoma
-
1:15
dr. sznol discusses advancements in immunotherapy for rcc
-
1:08
dr. sznol on managing patients beyond initial treatment in melanoma
-
1:05
dr. sznol discusses immunotherapy combinations in rcc
-
1:01
dr. sznol on managing toxicities in treatment of melanoma
-
7:54
combination therapies in renal cell carcinoma
-
1:22
dr. sznol discusses the combination of ipilimumab and nivolumab in melanoma
-
9:05
mrcc: when is tki/i-o combination therapy appropriate?
-
0:50
dr. sznol discusses immunotherapy in non-clear cell renal cancer
-
7:53
selecting an optimal second-line regimen for mrcc
-
0:53
dr. mario sznol describes nivolumab in advanced melanoma
-
3:47
other clinical trials in renal cell carcinoma
-
5:31
newly diagnosed metastatic renal cell carcinoma
-
0:56
dr. sznol on the use of immunotherapy in melanoma
-
7:38
patient selection and checkpoint inhibition in rcc
-
10:05
mario sznol, et al.